Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozurdex for Recalcitrant Diabetic Macular Edema
NCT01571232Phase 2Completed
- Sponsor
- Retina Macula Institute
- Start
- Apr 2012
- Primary completion
- Feb 2014
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ozurdex in diabetic macular edema (DME) (2 arms), sponsored by Retina Macula Institute. Primary endpoints: Change in Visual Acuity (Number of ETDRS Letters) at 6 months and Change in Central Foveal Thickness (Microns on High Resolution OCT) at 6 months. Started Apr 2012; status: completed.
02
Drugs
ozurdex
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT01571232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01571232.